Abstract Number: PB0191
Meeting: ISTH 2021 Congress
Background: Although the novel coronavirus disease 2019 (COVID-19) has been associated with an increased risk of venous thromboembolism (VTE), different VTE incidences are reported according to the population profile.
Aims: To compare risk factors, prophylaxis regimens, laboratory data, incidence and mortality rates of VTE associated with COVID-19 and non-COVID-19 patients, hospitalized in an institution with best practices in thromboprophylaxis.
Methods: We retrospectively analyzed all confirmed cases of VTE (pulmonary embolism [PE] and/or deep vein thrombosis [DVT]) reported in electronic medical records diagnosed at admission, during hospitalization or readmitted to the hospital within 90 days after discharge, between January/2020 and February/2021. Characteristics of VTE events associated with COVID-19 and VTE associated with other diseases (non-COVID patients), were compared.
Results: Over the study period, 177 patients presented VTE events (63.8% male, mean age 63.8±18.9 years, 38.4% confirmed COVID-19; 85% critically ill patients). Clinical characteristics were summarized in Table 1. In contrast to non-COVID group, COVID-19 patients were predominantly male (78% vs. 55%; p=0.002) and older (66 vs. 61 years old ;p=0.034), had less clinical risk factors for VTE, and developed VTE more frequently during hospital stay, despite using higher doses of enoxaparin (Table 1 and 2). Mortality rate was higher in the COVID group (38.2% vs. 5.5%; p<0.0001). Additionally, COVID group presented higher D-Dimer levels (17481 ± 26278 UI/ml vs. 7291 ± 11708 UI/ml; p=0.004), but similar C-reactive protein levels (12.5±11.8 vs.13.8±79.2; p=0.892). Regarding critically ill patients, COVID-19 was associated with an increased risk of VTE compared to non-COVID group (5.6% [34/602] vs. 0.5% [20/3690], unadjusted OR=10.98 [95% CI 6.3-19.2; p<0.00001]) (Table 2).
Conclusions: Despite of having less clinical risk factors for VTE and using greater doses of enoxaparin, COVID-19 patients had higher incidence of In-hospital VTE and higher mortality rate. These findings suggest that a hypercoagulability state could be induced by the coronavirus itself.
To cite this abstract in AMA style:Chindamo MC, Manhaes MB, Carvalho LD, Sardinha GG, Marques AM, Goudar HC, Nunes AB, Carmo Jr PR, Salgado DR. Differences of Venous Thromboembolism (VTE) Events in COVID-19 and Non-COVID-19 Hospitalized Patients [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). https://abstracts.isth.org/abstract/differences-of-venous-thromboembolism-vte-events-in-covid-19-and-non-covid-19-hospitalized-patients/. Accessed September 23, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/differences-of-venous-thromboembolism-vte-events-in-covid-19-and-non-covid-19-hospitalized-patients/